FDA Puts the Brakes on Avastin for Breast Cancer Treatment

An FDA advisory committee has recommended against the use of Avastin in breast cancer treatment. The decision was based upon new drug trials that demonstrated no demonstrable benefit in the treatment of breast cancer.
The recommendation is a set back for those who believed Avastin would prevent the disease’s progression. The FDA should make a final decision by Sept. 17. It is not required to follow the recommendations of advisory panels, but generally does.